发明名称 TRIAZOLE DERIVATIVES AS WNT SIGNALING PATHWAY INHIBITORS
摘要 The present invention relates to compounds of formula I, to processes for their preparation, to pharmaceutical formulations containing such compounds and to their use in therapy:;;Such compounds find particular use in the treatment and/or prevention of conditions or diseases which are affected by over-activation of signaling in the Wnt pathway and increased presence of nuclear β-catenin. For example, these may be used in preventing and/or retarding proliferation of tumor cells and metastasis, for example carcinomas such as colon carcinomas.
申请公布号 US2015322057(A1) 申请公布日期 2015.11.12
申请号 US201514753537 申请日期 2015.06.29
申请人 OSLO UNIVERSITY HOSPITAL, HF 发明人 Holsworth Daniel;Waaler Jo;Machon Ondrej;Krauss Stefan;Voronkov Andrey Edward
分类号 C07D413/14;C07D401/12 主分类号 C07D413/14
代理机构 代理人
主权项 1. A compound of general formula I: (wherein Z1 represents an unsaturated, 5- to 7-membered heterocyclic ring, or a group of the formula —(CH2)x—CO—NH—NH—CO—(CH2)y— wherein x and y independently denote an integer from 0 to 2; Z2 represents an aryl or heteroaryl group optionally substituted by one or more (e.g. 1, 2, 3 or 4) groups Ra; where each Ra may be identical or different and may be selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (preferably C1-3 alkyl), C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl (e.g. CF3), —CN, —NO2, —OR, —SR, —C(O)R, —C(O)OR, —OC(O)R, —OC(O)NR2, —C(O)NR2, —NR2, —NR—C(O)R, —NR—C(O)OR, —S(O)R, —S(O)2R, —S(O)OR or —S(O)2NR2 group (where each R is independently H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl or C2-6 alkynyl); R1 represents an aryl or heteroaryl group optionally substituted by one or more (e.g. 1, 2, 3 or 4) groups Rb; where each Rb may be identical or different and may be selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (preferably C1-3 alkyl) optionally interrupted by one or more —O—, —S— or —NR— groups (preferably by one or two —O— atoms), C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl (e.g. CF3), —CN, —NO2, —OR, —SR, —C(O)R, —C(O)OR, —OC(O)R, —OC(O)NR2, —C(O)NR2, —NR2, —NR—C(O)R, —NR—C(O)OR, —S(O)R, —S(O)2R, —S(O)OR or —S(O)2NR2 group (where each R is independently H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl or C2-6 alkynyl); R2 represents an aryl or heteroaryl group optionally substituted by one or more (e.g. 1, 2, 3 or 4) groups Rc; where each Rc may be identical or different and may be selected from halogen (i.e. F, Cl, Br, I), C1-6 alkyl (preferably C1-3 alkyl), C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl (e.g. CF3), —CN, —NO2, —OR, —SR, —C(O)R, —C(O)OR, —OC(O)R, —OC(O)NR2, —NR2, —NR—C(O)R, —NR—C(O)OR, —S(O)R, —S(O)2R, —S(O)OR or —S(O)2NR2 group (where each R is independently H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl or C2-6 alkynyl); L1 represents a C1-4 alkylene group optionally substituted by one or more (e.g. 1 or 2) groups Rd, wherein one or more (preferably one or two) methylene groups are each replaced by a group selected from —CRe═CRf—, —C≡C— and —C═C═C—; and wherein one or more (preferably one to three) methylene groups may each additionally be replaced by a group Y1;where each Y1 is independently selected from —O—, —S—, —NH—, —NR′″—, —NR′″-C(O)—, —C(O)—NR′″—, —C(O)—, —S(O2)—, —S(O)— and —CR′″═N— (where each R′″ is independently hydrogen or C1-6 alkyl);where each Rd may be identical or different and may be selected from C1-6 alkyl (preferably C1-3 alkyl), hydroxy, C1-6 alkoxy (e.g. C1-3 alkoxy) and halogen (i.e. F, Cl, Br and I, preferably F); andwhere Re and Rf are independently selected from H, C1-3 alkyl, halogen (e.g. F or Cl), C1-3 haloalkyl (e.g. —CF3), —CN, —NO2, —OR, —SR, —C(O)R, —C(O)OR, —OC(O)R, —OPO3R, —OSO2R and —OSiR4 (where each R is independently H, C1-6 alkyl or C1-6 haloalkyl); L2 represents a bond or an optionally substituted C1-6 alkylene group; and L3 represents a bond or an optionally substituted C1-6 alkylene group) or an isomer (e.g. stereoisomer), pharmaceutically acceptable salt or prodrug thereof.
地址 Oslo NO